Lipomatous Hypertrophy of the Interatrial Septum (LHIS) a Biomarker for Cardiovascular Protection? A Hypothesis Generating Case-Control Study.

While epicardial adipose tissue (EAT) is a known predictor of adverse cardiovascular outcomes, lipomatous hypertrophy of the interatrial septum (LHIS) is composed of metabolically active fat such as brown adipose tissue, which may exert a different effect. This study investigates the coronary atherosclerosis profile in patients with LHIS using CTA, compared with a propensity score-matched control group. A total of 142 patients were included ( = 71 with LHIS and = 71 controls) and propensity score-matched for age, gender, BMI, and the major CV risk factors (matching level, <0.05). CTA imaging parameters included HRP, coronary stenosis severity (CADRADS), and CAC score. : The mean age was 60.9 years +/- 10.6, there were nine (6.3%) women, and the mean BMI is 28.04 kg/m +/- 4.99. HRP prevalence was significantly lower in LHIS patients vs. controls (21.1% vs. 40.8%; < 0.011), while CAC ( = 0.827) and CADRADS ( = 0.329) were not different, and there was no difference in the obstructive disease rate. There was no difference in lipid panels (cholesterol, LDL, HDL, TG) and statin intake rate. HRP prevalence is lower in patients with LHIS than controls, while coronary stenosis severity and CAC score are not different. LHIS may serve as imaging biomarker for reversed CV risk.